Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- PMID: 30207593
- DOI: 10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Erratum in
-
Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2020 Jul;70(4):313. doi: 10.3322/caac.21609. Epub 2020 Apr 6. CA Cancer J Clin. 2020. PMID: 32767693 No abstract available.
Abstract
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
Keywords: cancer; epidemiology; incidence; survival.
© 2018 American Cancer Society.
Comment in
-
Oesophageal cancer: risks, prevention, and diagnosis.BMJ. 2019 Sep 6;366:l5391. doi: 10.1136/bmj.l5391. BMJ. 2019. PMID: 31492677 No abstract available.
Similar articles
-
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. CA Cancer J Clin. 2024. PMID: 38572751
-
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. CA Cancer J Clin. 2021. PMID: 33538338
-
The Global Burden of Cancer 2013.JAMA Oncol. 2015 Jul;1(4):505-27. doi: 10.1001/jamaoncol.2015.0735. JAMA Oncol. 2015. PMID: 26181261 Free PMC article.
-
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.Eur J Cancer. 2018 Nov;103:356-387. doi: 10.1016/j.ejca.2018.07.005. Epub 2018 Aug 9. Eur J Cancer. 2018. PMID: 30100160 Review.
-
Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.Lancet Oncol. 2022 Jun;23(6):719-728. doi: 10.1016/S1470-2045(22)00270-4. Epub 2022 May 9. Lancet Oncol. 2022. PMID: 35550275 Review.
Cited by
-
Viral sequence determines HLA-E-restricted T cell recognition of hepatitis B surface antigen.Nat Commun. 2024 Nov 22;15(1):10126. doi: 10.1038/s41467-024-54378-9. Nat Commun. 2024. PMID: 39578466 Free PMC article.
-
Fat fraction quantification by MRI predicts diagnosis and prognosis of HBV-related steatohepatitic hepatocellular carcinoma.Eur Radiol. 2024 Nov 22. doi: 10.1007/s00330-024-11151-2. Online ahead of print. Eur Radiol. 2024. PMID: 39576331
-
Modulation of miR-205 expression using a Cheiranthus cheiri phyto-nano hybrid as a potential therapeutic agent against breast cancer.RSC Adv. 2024 Nov 21;14(50):37286-37298. doi: 10.1039/d4ra03069a. eCollection 2024 Nov 19. RSC Adv. 2024. PMID: 39575377 Free PMC article.
-
Risk factors and survival prediction model establishment for prognosis in patients with radical resection of gallbladder cancer.World J Gastrointest Surg. 2024 Oct 27;16(10):3239-3252. doi: 10.4240/wjgs.v16.i10.3239. World J Gastrointest Surg. 2024. PMID: 39575289 Free PMC article.
-
Integrated analysis of single-cell, spatial and bulk RNA-sequencing identifies a cell-death signature for predicting the outcomes of head and neck cancer.Front Immunol. 2024 Nov 7;15:1487966. doi: 10.3389/fimmu.2024.1487966. eCollection 2024. Front Immunol. 2024. PMID: 39575251 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical